Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies.

[1]  G. M. Gelfuso,et al.  Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  G. K. Jain,et al.  Bioanalytical method development and validation of natamycin in rabbit tears and its application to ocular pharmacokinetic studies. , 2011, Journal of pharmaceutical and biomedical analysis.

[3]  A. Ludwig,et al.  Development of mucoadhesive poly(lactide-co-glycolide) nanoparticles for ocular application , 2011, Pharmaceutical development and technology.

[4]  J. Lovrić,et al.  A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. , 2010, Journal of pharmaceutical sciences.

[5]  S. Vyas,et al.  Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation , 2010, Journal of drug targeting.

[6]  P. Colombo,et al.  Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  A. Makky,et al.  Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. , 2010, Molecular pharmaceutics.

[8]  Shri Kant,et al.  Polymeric nanoparticulate system: a potential approach for ocular drug delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Jim Jiao.  Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. , 2008, Advanced drug delivery reviews.

[10]  Young Bin Choy,et al.  Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time. , 2008, Investigative ophthalmology & visual science.

[11]  G. Keshava,et al.  Mycotic keratitis: an overview of diagnosis and therapy , 2008, Mycoses.

[12]  W. Couet,et al.  Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans , 2008, Antimicrobial Agents and Chemotherapy.

[13]  R. Lewis.  Pharmacodynamic implications for use of antifungal agents. , 2007, Current opinion in pharmacology.

[14]  Y. Ali,et al.  Industrial perspective in ocular drug delivery. , 2006, Advanced drug delivery reviews.

[15]  P. Colombo,et al.  Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. , 2006, International journal of pharmaceutics.

[16]  A. Vila,et al.  Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. , 2006, Investigative ophthalmology & visual science.

[17]  J. Smart.  The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.

[18]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[19]  S. Kawakami,et al.  Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[20]  K R Wilhelmus,et al.  The Draize eye test. , 2001, Survey of ophthalmology.

[21]  D. K. Majumdar,et al.  Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. , 2000, International journal of pharmaceutics.

[22]  S. Burgalassi,et al.  Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[23]  N. Davies,et al.  Biopharmaceutical Considerations In Topical Ocular Drug Delivery , 2000, Clinical and experimental pharmacology & physiology.

[24]  Robert Gurny,et al.  Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. , 1999, International journal of pharmaceutics.

[25]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[26]  T. Kuriakose,et al.  Keratitis due to Cephaliophora irregularis Thaxter. , 1995, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[27]  T. A. Hatton,et al.  Poly(ethylene oxide)-poly(propylene oxide )-poly (ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling , 1995 .

[28]  J. Kreuter,et al.  Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye. I: In vitro and in vivo characterisation , 1994 .

[29]  E. Korn,et al.  Single bilayer liposomes prepared without sonication. , 1973, Biochimica et biophysica acta.

[30]  Alejandro Sánchez,et al.  Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity , 2005, Pharmaceutical Research.

[31]  M. Srinivasan,et al.  Corneal blindness: a global perspective. , 2001, Bulletin of the World Health Organization.

[32]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[33]  M. Alonso,et al.  Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions , 1997 .

[34]  A. Joshi.  Microparticulates for ophthalmic drug delivery. , 1994, Journal of ocular pharmacology.

[35]  P. Asbell,et al.  Ulcerative keratitis. Survey of 30 years' laboratory experience. , 1982, Archives of ophthalmology.